What does Dianthus Therapeutics, Inc. do?
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the…
What is Dianthus Therapeutics, Inc.'s P/E and P/B ratio?
Dianthus Therapeutics, Inc. has a P/E ratio of -18.5 and a P/B ratio of 3.75.
What is Dianthus Therapeutics, Inc.'s debt-to-equity ratio?
Dianthus Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Dianthus Therapeutics, Inc. owe compared with what it owns?
Dianthus Therapeutics, Inc. owes $0.03 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Dianthus Therapeutics, Inc.'s Positivity rank?
Dianthus Therapeutics, Inc. is ranked #4,904 of 6,774 companies globally and #2,571 of 4,000 in United States on PositoAI, with a Positivity Score of 18,780.
Does Dianthus Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Dianthus Therapeutics, Inc..
Where can I read the latest news about Dianthus Therapeutics, Inc.?
Recent headlines about Dianthus Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Dianthus Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Dianthus Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.